264 related articles for article (PubMed ID: 17010679)
1. Epidemiological dynamics of antimonial resistance in Leishmania donovani: genotyping reveals a polyclonal population structure among naturally-resistant clinical isolates from Nepal.
Laurent T; Rijal S; Yardley V; Croft S; De Doncker S; Decuypere S; Khanal B; Singh R; Schönian G; Kuhls K; Chappuis F; Dujardin JC
Infect Genet Evol; 2007 Mar; 7(2):206-12. PubMed ID: 17010679
[TBL] [Abstract][Full Text] [Related]
2. Assessing aquaglyceroporin gene status and expression profile in antimony-susceptible and -resistant clinical isolates of Leishmania donovani from India.
Mandal S; Maharjan M; Singh S; Chatterjee M; Madhubala R
J Antimicrob Chemother; 2010 Mar; 65(3):496-507. PubMed ID: 20067981
[TBL] [Abstract][Full Text] [Related]
3. Leishmania donovani: an in vitro study of antimony-resistant amphotericin B-sensitive isolates.
Sharief AH; Gasim Khalil EA; Theander TG; Kharazmi A; Omer SA; Ibrahim ME
Exp Parasitol; 2006 Dec; 114(4):247-52. PubMed ID: 16716301
[TBL] [Abstract][Full Text] [Related]
4. Leishmania donovani: genetic diversity of isolates from Sudan characterized by PCR-based RAPD.
Hamad SH; Khalil EA; Musa AM; Ibrahim ME; Younis BM; Elfaki ME; El-Hassan AM;
Exp Parasitol; 2010 Aug; 125(4):389-93. PubMed ID: 20346944
[TBL] [Abstract][Full Text] [Related]
5. Studies on stibanate resistant Leishmania donovani isolates of Indian origin.
Pal S; Mandal A; Duttagupta S
Indian J Exp Biol; 2001 Mar; 39(3):249-54. PubMed ID: 11495284
[TBL] [Abstract][Full Text] [Related]
6. [Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009].
Rosenthal E; Delaunay P; Jeandel PY; Haas H; Pomares-Estran C; Marty P
Med Mal Infect; 2009 Oct; 39(10):741-4. PubMed ID: 19783391
[TBL] [Abstract][Full Text] [Related]
7. Novel mechanism of drug resistance in kala azar field isolates.
Singh N; Singh RT; Sundar S
J Infect Dis; 2003 Aug; 188(4):600-7. PubMed ID: 12898450
[TBL] [Abstract][Full Text] [Related]
8. Possibility of membrane modification as a mechanism of antimony resistance in Leishmania donovani.
Kothari H; Kumar P; Sundar S; Singh N
Parasitol Int; 2007 Mar; 56(1):77-80. PubMed ID: 17169604
[TBL] [Abstract][Full Text] [Related]
9. Development and evaluation of different PCR-based typing methods for discrimination of Leishmania donovani isolates from Nepal.
Bhattarai NR; Dujardin JC; Rijal S; De Doncker S; Boelaert M; Van der Auwera G
Parasitology; 2010 May; 137(6):947-57. PubMed ID: 20109247
[TBL] [Abstract][Full Text] [Related]
10. The overexpression of genes of thiol metabolism contribute to drug resistance in clinical isolates of visceral leishmaniasis (kala azar) in India.
Singh N; Chatterjee M; Sundar S
Parasit Vectors; 2014 Dec; 7():596. PubMed ID: 25515494
[TBL] [Abstract][Full Text] [Related]
11. Antimony-resistant Leishmania donovaniin eastern Sudan: incidence and in vitro correlation.
Abdo MG; Elamin WM; Khalil EA; Mukhtar MM
East Mediterr Health J; 2003 Jul; 9(4):837-43. PubMed ID: 15748080
[TBL] [Abstract][Full Text] [Related]
12. Multilocus microsatellite typing (MLMT) reveals genetic homogeneity of Leishmania donovani strains in the Indian subcontinent.
Alam MZ; Kuhls K; Schweynoch C; Sundar S; Rijal S; Shamsuzzaman AK; Raju BV; Salotra P; Dujardin JC; Schönian G
Infect Genet Evol; 2009 Jan; 9(1):24-31. PubMed ID: 18957333
[TBL] [Abstract][Full Text] [Related]
13. [A case of antimony resistant kala-azar cured with amphotericin B].
Chen SB; Yang CM; Zhang CJ
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2007 Jun; 25(3):inside front page. PubMed ID: 18038767
[No Abstract] [Full Text] [Related]
14. Characterization of natural antimony resistance in Leishmania donovani isolates.
Mittal MK; Rai S; Ashutosh ; Ravinder ; Gupta S; Sundar S; Goyal N
Am J Trop Med Hyg; 2007 Apr; 76(4):681-8. PubMed ID: 17426170
[TBL] [Abstract][Full Text] [Related]
15. Genetic typing reveals monomorphism between antimony sensitive and resistant Leishmania donovani isolates from visceral leishmaniasis or post kala-azar dermal leishmaniasis cases in India.
Subba Raju BV; Gurumurthy S; Kuhls K; Bhandari V; Schnonian G; Salotra P
Parasitol Res; 2012 Oct; 111(4):1559-68. PubMed ID: 22752721
[TBL] [Abstract][Full Text] [Related]
16. Antimonial treatment of visceral leishmaniasis: are current in vitro susceptibility assays adequate for prognosis of in vivo therapy outcome?
Rijal S; Yardley V; Chappuis F; Decuypere S; Khanal B; Singh R; Boelaert M; De Doncker S; Croft S; Dujardin JC
Microbes Infect; 2007 Apr; 9(4):529-35. PubMed ID: 17350306
[TBL] [Abstract][Full Text] [Related]
17. Genetic markers for antimony resistant clinical isolates differentiation from Indian Kala-azar.
Khanra S; Sarraf NR; Das S; Das AK; Roy S; Manna M
Acta Trop; 2016 Dec; 164():177-184. PubMed ID: 27629023
[TBL] [Abstract][Full Text] [Related]
18. Increased metacyclogenesis of antimony-resistant Leishmania donovani clinical lines.
Ouakad M; Vanaerschot M; Rijal S; Sundar S; Speybroeck N; Kestens L; Boel L; De Doncker S; Maes I; Decuypere S; Dujardin JC
Parasitology; 2011 Sep; 138(11):1392-9. PubMed ID: 21819638
[TBL] [Abstract][Full Text] [Related]
19. Molecular Preadaptation to Antimony Resistance in Leishmania donovani on the Indian Subcontinent.
Dumetz F; Cuypers B; Imamura H; Zander D; D'Haenens E; Maes I; Domagalska MA; Clos J; Dujardin JC; De Muylder G
mSphere; 2018 Apr; 3(2):. PubMed ID: 29669889
[TBL] [Abstract][Full Text] [Related]
20. The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine.
Yardley V; Croft SL; De Doncker S; Dujardin JC; Koirala S; Rijal S; Miranda C; Llanos-Cuentas A; Chappuis F
Am J Trop Med Hyg; 2005 Aug; 73(2):272-5. PubMed ID: 16103588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
